A Third COVID-19 Vaccine Looks Very Promising

  • Author: ChemistryViews
  • Published: 24 November 2020
  • Copyright: Wiley-VCH GmbH
  • Associated Suppliers: AstraZeneca plc, Cambridge, UK
thumbnail image: A Third COVID-19 Vaccine Looks Very Promising

AZD1222 is the vaccine developed by the University of Oxford, UK, and the pharma company AstraZeneca. After Moderna and Pfizer and BioNTech have published first very positive results from their ongoing Phase 3 studies, an interim analysis of clinical trials of AZD1222 also shows, according to a press release, that the vaccine is highly effective in preventing COVID-19. No hospitalizations or severe cases of the disease were reported in participants who received the vaccine. In total, there were 131 cases of COVID-19 in the interim analysis.

The vaccine is more effective when half a dose is administered first and a full dose a month later (90 %) than when two full doses are administered (62 %). This has caused discussions; AstraZeneca has so far not given a scientific explanation, only speculations. It could be possible, for example, that lower vaccine doses could better stimulate T cells, which support the production of antibodies. AZD1222 was well tolerated across both dosing regimens.

AstraZeneca announced that it will immediately prepare to submit the data to authorities around the world for conditional or early approval. The company plans to apply to the World Health Organization (WHO) for an Emergency Use Listing to speed up vaccine availability in low-income countries, and to submit a full analysis of interim results for publication in a peer-reviewed journal.

The global trials are evaluating participants aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. The vaccine can be stored, transported, and handled at normal refrigerated conditions (2-8 °C) for at least six months and administered in existing health care facilities.

AZD1222 uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.


 

Also of Interest

  • Collection: SARS-CoV-2 Virus
    What we know about the new coronavirus and COVID-19
  • Clever Picture: Searching for a Vaccine
    4 August 2020
    Picture describes what happens during vaccination and gives a snapshot of which Covid-19 vaccine candidates are in which clinical phases
  •  

     

     

     

Article Views: 1105

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH